Correlation Between Halozyme Therapeutics and Biomarin Pharmaceutical

Can any of the company-specific risk be diversified away by investing in both Halozyme Therapeutics and Biomarin Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Halozyme Therapeutics and Biomarin Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Halozyme Therapeutics and Biomarin Pharmaceutical, you can compare the effects of market volatilities on Halozyme Therapeutics and Biomarin Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Halozyme Therapeutics with a short position of Biomarin Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Halozyme Therapeutics and Biomarin Pharmaceutical.

Diversification Opportunities for Halozyme Therapeutics and Biomarin Pharmaceutical

0.63

Correlation Coefficient

Halozyme Therapeutics  Biomarin Pharmaceutical

Poor diversification

The 3 months correlation between Halozyme and Biomarin is 0.63. Overlapping area represents the amount of risk that can be diversified away by holding Halozyme Therapeutics and Biomarin Pharmaceutical in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biomarin Pharmaceutical and Halozyme Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Halozyme Therapeutics are associated (or correlated) with Biomarin Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biomarin Pharmaceutical has no effect on the direction of Halozyme Therapeutics i.e., Halozyme Therapeutics and Biomarin Pharmaceutical go up and down completely randomly.

Pair Corralation between Halozyme Therapeutics and Biomarin Pharmaceutical

Given the investment horizon of 90 days Halozyme Therapeutics is expected to generate 1.47 times more return on investment than Biomarin Pharmaceutical. However, Halozyme Therapeutics is 1.47 times more volatile than Biomarin Pharmaceutical. It trades about -0.08 of its potential returns per unit of risk. Biomarin Pharmaceutical is currently generating about -0.19 per unit of risk. If you would invest  6,122  in Halozyme Therapeutics on August 31, 2024 and sell it today you would lose (1,275) from holding Halozyme Therapeutics or give up 20.83% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Halozyme Therapeutics  vs.  Biomarin Pharmaceutical

Halozyme Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Halozyme Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Biomarin Pharmaceutical

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Biomarin Pharmaceutical has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Halozyme Therapeutics and Biomarin Pharmaceutical

The main advantage of trading using opposite Halozyme Therapeutics and Biomarin Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Halozyme Therapeutics position performs unexpectedly, Biomarin Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will offset losses from the drop in Biomarin Pharmaceutical's long position.

The idea behind Halozyme Therapeutics and Biomarin Pharmaceutical pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.